Fig. 1: CONSORT diagram for the FX-909-CLINPRO-1 phase 1 (part A) study.
From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
A total of 68 patients were screened and 56 patients were enrolled across four doses.
Fig. 1: CONSORT diagram for the FX-909-CLINPRO-1 phase 1 (part A) study. | Nature Medicine
